STOCK TITAN

Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Recursion Pharmaceuticals director Christopher Gibson converted 20,000 shares of Class B Common Stock into 20,000 shares of Class A Common Stock on March 9, 2026. The conversion price was reported as $0.00 per share.

On the same date, he made a bona fide gift of 20,000 Class A shares, leaving him with 906,556 Class A shares directly owned and 4,523,334 Class B shares directly owned after these transactions.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gibson Christopher

(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET

(Street)
SALT LAKE CITY UT 84101

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 03/09/2026 C(1)(2) 20,000 A $0 926,556 D
Class A Common Stock 03/09/2026 G(2) 20,000 D $0 906,556 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock $0(1) 03/09/2026 C 20,000 (1) (1) Class A Common Stock 20,000 $0 4,523,334 D
Class B Common Stock $0 (1) (1) Class A Common Stock 0 386,000 I by LAHWRAN-3 LLC(3)
Class B Common Stock $0 (1) (1) Class A Common Stock 0 388,000 I by LAHWRAN-4 LLC(4)
Class B Common Stock $0 (1) (1) Class A Common Stock 0 50,000 I by Gibson Family Trust(5)
Stock Option (Right to Buy) $7.25 (6) 02/03/2035 Class A Common Stock 0 1,050,567 D
Stock Option (Right to Buy) $10.09 (7) 02/09/2034 Class A Common Stock 0 666,898 D
Stock Option (Right to Buy) $8.55 (8) 02/01/2033 Class A Common Stock 0 813,600 D
Stock Option (Right to Buy) $11.4 (9) 02/04/2032 Class A Common Stock 0 399,002 D
Stock Option (Right to Buy) $11.4 02/04/2022 02/04/2032 Class A Common Stock 0 5,436 D
Stock Option (Right to Buy) $2.48 (10) 12/30/2030 Class A Common Stock 0 282,500 D
Explanation of Responses:
1. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
3. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
4. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
5. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
7. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
9. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
10. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Remarks:
/s/ Kyle Nelson, attorney-in-fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Christopher Gibson report for RXRX?

Christopher Gibson reported converting 20,000 Class B shares into 20,000 Class A shares, then gifting 20,000 Class A shares. These moves changed only the mix and ownership of his holdings, without any open-market buying or selling activity.

How many Recursion (RXRX) shares does Christopher Gibson hold after this Form 4?

After the reported transactions, Christopher Gibson directly holds 906,556 shares of Class A Common Stock and 4,523,334 shares of Class B Common Stock. These figures reflect his position immediately following the 20,000-share conversion and subsequent 20,000-share bona fide gift.

Did Christopher Gibson buy or sell Recursion (RXRX) shares on the market?

The filing shows no open-market purchases or sales. Instead, Gibson converted 20,000 Class B shares into Class A shares at a stated price of $0.00 and then transferred 20,000 Class A shares as a bona fide gift, which involves no sale proceeds.

What does the Class B to Class A conversion mean for RXRX’s insider structure?

Gibson’s conversion of 20,000 Class B shares into 20,000 Class A shares simply changes the class of part of his stake. Footnotes state each Class B share is convertible into one Class A share at the holder’s option and has no expiration date.

Were any Recursion (RXRX) derivative or option positions affected in this Form 4?

The reported conversion involved Class B shares that are themselves convertible into Class A shares. The filing also lists stock options with exercise prices between $2.48 and $11.40 and expirations from 2030 to 2035, indicating additional potential future Class A exposure.
Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

View RXRX Stock Overview

RXRX Rankings

RXRX Latest News

RXRX Latest SEC Filings

RXRX Stock Data

1.82B
506.92M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SALT LAKE CITY